INTRODUCTION
The novel coronavirus infection (COVID-19) was prevalent in Wuhan since
December 2019, including pregnant women1. In Wuhan,
these patients represented 0.24% of all reported cases with
COVID-192. COVID-19 affects the entire pregnancy;
however, current research is mostly about pregnancy during the third
trimester and peripartum2-4. In New York, of the 215
women screened for severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) on admission using nasopharyngeal swabs, 33 women (15.4%)
were found positive. Of these positive cases, four had fever or other
symptoms of COVID-19, while 29 were asymptomatic3.
Currently, there are a few reports on the outcome of COVID-19 in
pregnant women during the first and second trimester, as well
post-recovery. The effect of COVID-19 on pregnancy remains unclear,
which obstetricians and neonatologists. Recent researches indicated that
there is no clear evidence of intrauterine infection in pregnancy with
COVID-19 during the third trimester2,5. However, both
SARS-CoV-2 IgM and IgG were detected in newborns of infected mothers,
which question the possibility of intrauterine
infection6,7. Some studies claimed that a positive IgM
test result could not be regarded as the definite evidence of vertical
transmission8. Our previous study reported the
clinical characteristics and placental pathological analysis of three
peripartum women with COVID-199. We noted no severe
adverse pregnancy outcomes or morphological changes related to
infection. All samples were negative for the SARS-CoV-2 nucleic
acid9. We concluded that COVID-19 intrauterine
infection does not occur during the third trimester.
The aim of our current study is to determine the safety and postpartum
outcomes in pregnant patients infected from early pregnancy (first
and/or second trimester) with COVID-19.